Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of NIR178 + PDR001 in advanced solid tumors and non-Hodgkin lymphoma (Japan)
jRCT2080223865Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of taminadenant and spartalizumab in renal cell carcinoma (RCC), pancreatic cancer (PC), transitional cell carcinoma (TCC) and 9 more (4 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of NIR178 + PDR001 and Pharmacokinetics of NIR178 (single agent and in combination with PDR001). Started Apr 2018; status: completed.
02
Drugs
taminadenantspartalizumab
03
Conditions
renal cell carcinoma (RCC)pancreatic cancer (PC)transitional cell carcinoma (TCC)head and neck squamous cell carcinoma (HNSCC)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2080223865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223865.